Recent Updates
Recently added Catalysts
TLX Negative Sentiment

Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 9, 2026 to Discuss Your Rights – TLX

Key Takeaway: Telix Pharmaceuticals Ltd. is facing a securities fraud class action lawsuit for allegedly making materially false statements during the period of February 21, 2025, to August 28, 2025. Accusations include overstating the company's progress with prostate cancer candidates and misrepresenting the reliability of its supply chain and partners. Shareholders are encouraged to register with the Gross Law Firm before the January 9, 2026 deadline to discuss their rights and potential participation in the case. The firm emphasizes that registration does not obligate shareholders to any costs.
Price reaction · baseline $9.85 (2025-12-05 close) · 4 other TLX headline(s) in the window, move may be shared
day 0 close · peak
-1.8%

Market Sentiment Analysis

CONCERNS & RISKS

  • Allegations of securities fraud due to materially false statements made by the company.
  • Concerns over overstated progress in prostate cancer therapeutics.
  • Quality of Telix's supply chain and partner relationships were allegedly exaggerated.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX).
Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 21, 2025 to August 28, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) defendants materially overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants’ statements about Telix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
DEADLINE: January 9, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=179748&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of TLX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is January 9, 2026. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor

Frequently Asked Questions

What is the class period for Telix Pharmaceuticals shareholders?

The class period for Telix Pharmaceuticals is from February 21, 2025, to August 28, 2025.

What allegations are being made against Telix Pharmaceuticals?

The allegations include misleading statements about prostate cancer candidates and the quality of the supply chain.

How can shareholders participate in the class action?

Shareholders can register online to participate by providing their information.

When is the deadline to seek lead plaintiff status?

The deadline to seek lead plaintiff status is January 9, 2026.

What services does the Gross Law Firm provide for investors?

The Gross Law Firm offers monitoring and updates throughout the case for registered investors.

Last updated: Dec 8, 2025